Journal article
IMST-53. THE EFFICACY OF CD133 BiTEs AND CAR-T CELLS IN PRECLINICAL MODEL OF RECURRENT GLIOBLASTOMA
Abstract
Glioblastoma (GBM) is a uniformly fatal primary brain tumor, characterized by extensive cellular heterogeneity. Numerous studies have implicated CD133+ brain tumor initiating cells (BTICs) as drivers of chemo- and radio-resistance in GBM. We have recently demonstrated that a CD133-driven gene signature is predictive of poor overall survival and targeting CD133+ treatment-refractory cells may be an effective strategy to block GBM recurrence. …
Authors
Vora P; Chokshi C; Qazi M; Venugopal C; Mahendram S; Singh M; Adams J; London M; Bakhshinyan D; Subapanditha M
Journal
Neuro-Oncology, Vol. 18, No. suppl_6, pp. vi98–vi98
Publisher
Oxford University Press (OUP)
Publication Date
November 1, 2016
DOI
10.1093/neuonc/now212.409
ISSN
1522-8517